Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance...

Area of Science:

• Oncology
• Biomarker Discovery
• Extracellular Vesicle Research

Background:

• Ovarian cancer (OC) screening requires high sensitivity and specificity due to its low incidence.
• Current screening methods, like CA125, have limitations in accuracy.
• Tumor-associated extracellular vesicles (EVs) offer a potential source for novel biomarkers.

Purpose of the Study:

• To evaluate the utility of a novel blood test for detecting OC by analyzing multiple biomarkers on EVs.
• To assess the sensitivity and specificity of the Mercy Halo Ovarian Cancer Test (OC Test) compared to CA125.
• To determine the potential of the OC Test as a screening tool for ovarian cancer.

Main Methods:

• Immunoaffinity capture of tumor-associated EVs from blood samples.
• Proximity-ligation real-time quantitative PCR to detect combinations of up to three biomarkers on EVs.
• Development and validation of a data interpretation algorithm and cutoff for cancer detection.
• Case-control studies using training and independent verification sets of plasma and serum samples.

Main Results:

• The OC Test demonstrated high specificity (97.0%) and high-grade serous carcinoma (HGSC) sensitivity (97.0%) in the verification set.
• The test achieved an area under the curve of 0.97, indicating strong diagnostic performance.
• It detected 73.5% of non-HGSC OC cases and showed fewer false positives than CA125 in subjects with benign conditions.

Conclusions:

• The novel OC Test, utilizing multiplexed EV biomarker detection, shows significant potential for ovarian cancer screening.
• Its high sensitivity and specificity, coupled with a reduced false-positive rate compared to CA125, suggest clinical utility.
• Further validation is warranted to confirm its role in early OC detection strategies.